Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies

Z. Romay-Penabad, A. L. Carrera Marin, R. Willis, W. Weston-Davies, S. Machin, H. Cohen, A. Brasier, Emilio Gonzalez

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis. Groups of C57BL/6J mice (n-=-5) received either IgG from a patient with antiphospholipid syndrome (APS) or control IgG from normal human serum (NHS). Each of these groups of mice had IgG administration preceded by either rEV576, or phosphate buffer control. For each of the four treatment groups, the size of induced thrombus, tissue factor activity in carotid homogenates, anticardiolipin and anti-β2glycoprotein I (anti-β2GPI) levels were measured 72-h after the first injection. Mice treated with IgG-APS had significantly higher titers of anticardiolipin antibodies and anti-β2GPI at thrombus induction compared with those treated with IgG-NHS. The IgG-APS/phosphate buffer treatment induced significantly larger thrombi and tissue factor activity compared with other groups. Mice treated with IgG-APS/rEV576 had significantly smaller thrombi and reduced tissue factor activity than those treated with IgG-APS/phosphate buffer. The data confirm involvement of complement activation in antiphospholipid antibody-mediated thrombogenesis and suggest that complement inhibition might ameliorate this effect.

Original languageEnglish (US)
Pages (from-to)1324-1326
Number of pages3
JournalLupus
Volume23
Issue number12
DOIs
StatePublished - Oct 8 2014

Fingerprint

Complement Inactivating Agents
Complement C5
Antiphospholipid Antibodies
Immunoglobulin G
Antiphospholipid Syndrome
Thrombosis
Thromboplastin
Buffers
Complement Activation
Phosphates
Anticardiolipin Antibodies
Serum
Inbred C57BL Mouse
Recombinant Proteins

Keywords

  • aPL-mediated thrombogenesis
  • Complement inhibition
  • coversin

ASJC Scopus subject areas

  • Rheumatology

Cite this

Romay-Penabad, Z., Carrera Marin, A. L., Willis, R., Weston-Davies, W., Machin, S., Cohen, H., ... Gonzalez, E. (2014). Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus, 23(12), 1324-1326. https://doi.org/10.1177/0961203314546022

Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. / Romay-Penabad, Z.; Carrera Marin, A. L.; Willis, R.; Weston-Davies, W.; Machin, S.; Cohen, H.; Brasier, A.; Gonzalez, Emilio.

In: Lupus, Vol. 23, No. 12, 08.10.2014, p. 1324-1326.

Research output: Contribution to journalArticle

Romay-Penabad, Z, Carrera Marin, AL, Willis, R, Weston-Davies, W, Machin, S, Cohen, H, Brasier, A & Gonzalez, E 2014, 'Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies', Lupus, vol. 23, no. 12, pp. 1324-1326. https://doi.org/10.1177/0961203314546022
Romay-Penabad Z, Carrera Marin AL, Willis R, Weston-Davies W, Machin S, Cohen H et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct 8;23(12):1324-1326. https://doi.org/10.1177/0961203314546022
Romay-Penabad, Z. ; Carrera Marin, A. L. ; Willis, R. ; Weston-Davies, W. ; Machin, S. ; Cohen, H. ; Brasier, A. ; Gonzalez, Emilio. / Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. In: Lupus. 2014 ; Vol. 23, No. 12. pp. 1324-1326.
@article{f7e017affc784ed0a23967dc68c45202,
title = "Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies",
abstract = "Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis. Groups of C57BL/6J mice (n-=-5) received either IgG from a patient with antiphospholipid syndrome (APS) or control IgG from normal human serum (NHS). Each of these groups of mice had IgG administration preceded by either rEV576, or phosphate buffer control. For each of the four treatment groups, the size of induced thrombus, tissue factor activity in carotid homogenates, anticardiolipin and anti-β2glycoprotein I (anti-β2GPI) levels were measured 72-h after the first injection. Mice treated with IgG-APS had significantly higher titers of anticardiolipin antibodies and anti-β2GPI at thrombus induction compared with those treated with IgG-NHS. The IgG-APS/phosphate buffer treatment induced significantly larger thrombi and tissue factor activity compared with other groups. Mice treated with IgG-APS/rEV576 had significantly smaller thrombi and reduced tissue factor activity than those treated with IgG-APS/phosphate buffer. The data confirm involvement of complement activation in antiphospholipid antibody-mediated thrombogenesis and suggest that complement inhibition might ameliorate this effect.",
keywords = "aPL-mediated thrombogenesis, Complement inhibition, coversin",
author = "Z. Romay-Penabad and {Carrera Marin}, {A. L.} and R. Willis and W. Weston-Davies and S. Machin and H. Cohen and A. Brasier and Emilio Gonzalez",
year = "2014",
month = "10",
day = "8",
doi = "10.1177/0961203314546022",
language = "English (US)",
volume = "23",
pages = "1324--1326",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies

AU - Romay-Penabad, Z.

AU - Carrera Marin, A. L.

AU - Willis, R.

AU - Weston-Davies, W.

AU - Machin, S.

AU - Cohen, H.

AU - Brasier, A.

AU - Gonzalez, Emilio

PY - 2014/10/8

Y1 - 2014/10/8

N2 - Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis. Groups of C57BL/6J mice (n-=-5) received either IgG from a patient with antiphospholipid syndrome (APS) or control IgG from normal human serum (NHS). Each of these groups of mice had IgG administration preceded by either rEV576, or phosphate buffer control. For each of the four treatment groups, the size of induced thrombus, tissue factor activity in carotid homogenates, anticardiolipin and anti-β2glycoprotein I (anti-β2GPI) levels were measured 72-h after the first injection. Mice treated with IgG-APS had significantly higher titers of anticardiolipin antibodies and anti-β2GPI at thrombus induction compared with those treated with IgG-NHS. The IgG-APS/phosphate buffer treatment induced significantly larger thrombi and tissue factor activity compared with other groups. Mice treated with IgG-APS/rEV576 had significantly smaller thrombi and reduced tissue factor activity than those treated with IgG-APS/phosphate buffer. The data confirm involvement of complement activation in antiphospholipid antibody-mediated thrombogenesis and suggest that complement inhibition might ameliorate this effect.

AB - Activation of the complement cascade is an important mechanism for antiphospholipid antibody-mediated thrombosis. We examined the effects of rEV576 (coversin), a recombinant protein inhibitor of complement factor 5 activation, on antiphospholipid antibody-mediated tissue factor up-regulation and thrombosis. Groups of C57BL/6J mice (n-=-5) received either IgG from a patient with antiphospholipid syndrome (APS) or control IgG from normal human serum (NHS). Each of these groups of mice had IgG administration preceded by either rEV576, or phosphate buffer control. For each of the four treatment groups, the size of induced thrombus, tissue factor activity in carotid homogenates, anticardiolipin and anti-β2glycoprotein I (anti-β2GPI) levels were measured 72-h after the first injection. Mice treated with IgG-APS had significantly higher titers of anticardiolipin antibodies and anti-β2GPI at thrombus induction compared with those treated with IgG-NHS. The IgG-APS/phosphate buffer treatment induced significantly larger thrombi and tissue factor activity compared with other groups. Mice treated with IgG-APS/rEV576 had significantly smaller thrombi and reduced tissue factor activity than those treated with IgG-APS/phosphate buffer. The data confirm involvement of complement activation in antiphospholipid antibody-mediated thrombogenesis and suggest that complement inhibition might ameliorate this effect.

KW - aPL-mediated thrombogenesis

KW - Complement inhibition

KW - coversin

UR - http://www.scopus.com/inward/record.url?scp=84908664176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908664176&partnerID=8YFLogxK

U2 - 10.1177/0961203314546022

DO - 10.1177/0961203314546022

M3 - Article

C2 - 25228739

AN - SCOPUS:84908664176

VL - 23

SP - 1324

EP - 1326

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 12

ER -